KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Equity Average (2016 - 2025)

Pacific Biosciences Of California has reported Equity Average over the past 15 years, most recently at $20.7 million for Q4 2025.

  • Quarterly results put Equity Average at $20.7 million for Q4 2025, down 95.68% from a year ago — trailing twelve months through Dec 2025 was $20.7 million (down 95.68% YoY), and the annual figure for FY2025 was $256.0 million, down 57.62%.
  • Equity Average for Q4 2025 was $20.7 million at Pacific Biosciences Of California, down from $48.8 million in the prior quarter.
  • Over the last five years, Equity Average for PACB hit a ceiling of $762.8 million in Q1 2022 and a floor of $20.7 million in Q4 2025.
  • Median Equity Average over the past 5 years was $582.8 million (2022), compared with a mean of $481.7 million.
  • Biggest five-year swings in Equity Average: skyrocketed 434.2% in 2021 and later plummeted 95.68% in 2025.
  • Pacific Biosciences Of California's Equity Average stood at $269.4 million in 2021, then surged by 120.77% to $594.7 million in 2022, then rose by 23.17% to $732.5 million in 2023, then crashed by 34.49% to $479.9 million in 2024, then plummeted by 95.68% to $20.7 million in 2025.
  • The last three reported values for Equity Average were $20.7 million (Q4 2025), $48.8 million (Q3 2025), and $76.6 million (Q2 2025) per Business Quant data.